Supernus Pharmaceuticals (SUPN) EBITDA Margin (2011 - 2025)
Supernus Pharmaceuticals (SUPN) reported EBITDA Margin of 1.86% for Q4 2025, down 1415.0% year-over-year from 0.14% in Q4 2024, and up 94.06% quarter-over-quarter from 31.35% in Q3 2025.
Supernus Pharmaceuticals (SUPN) EBITDA Margin (2011 - 2025) Analysis & Trends
Supernus Pharmaceuticals (SUPN) has 15 years of EBITDA Margin data on file, last reported at 1.86% in Q4 2025.
- EBITDA Margin for Q4 2025 came in at 1.86%, down 1415.0% year-over-year; the trailing twelve-month figure through Dec 2025 was 8.88% (down 2122.0% YoY), and the FY2025 annual result was 8.66%, down 2100.0% from the prior year.
- EBITDA Margin grew to 1.86% in Q4 2025 per SUPN's latest filing, from 31.35% in the prior quarter.
- Over five years, EBITDA Margin peaked at 24.14% in Q2 2021 and troughed at 31.35% in Q3 2025.
- A 5-year average of 4.79% and a median of 4.56% in 2021 frame the typical range for EBITDA Margin.
- The sharpest annual moves came in 2024 and 2025: EBITDA Margin soared 2638 bps in 2024, then sank 5460 bps in 2025.
- A 5-year view of EBITDA Margin shows it stood at 3.83% in 2021, then jumped by 435 bps to 20.52% in 2022, then plunged by 103 bps to 0.61% in 2023, then jumped by 2128 bps to 12.29% in 2024, then sank by 115 bps to 1.86% in 2025.
- Business Quant data shows SUPN's EBITDA Margin at 1.86% in Q4 2025, 31.35% in Q3 2025, and 7.34% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | 16.37% |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | 36.83% |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | 41.69% |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | -1.01% |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | 22.74% |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | 22.39% |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | -170.35% |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | 21.55% |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | -16.25% |
| 10 | Supernus Pharmaceuticals | 2.57 Bn | 2.19 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1.86% |
| Sep 30, 2025 | -31.35% |
| Jun 30, 2025 | 7.34% |
| Mar 31, 2025 | -7.87% |
| Dec 31, 2024 | 12.29% |
| Sep 30, 2024 | 23.25% |
| Jun 30, 2024 | 13.41% |
| Mar 31, 2024 | -2.20% |
| Dec 31, 2023 | -0.61% |
| Sep 30, 2023 | 5.29% |
| Jun 30, 2023 | -12.97% |
| Mar 31, 2023 | 3.37% |
| Dec 31, 2022 | 20.52% |
| Sep 30, 2022 | -0.86% |
| Jun 30, 2022 | 6.67% |
| Mar 31, 2022 | 1.29% |
| Dec 31, 2021 | 3.83% |
| Sep 30, 2021 | 21.96% |
| Jun 30, 2021 | 24.14% |
| Mar 31, 2021 | 10.09% |